Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Reports advance knowledge in cancer therapy research
November 18th, 2005
Reports from the United States and Ireland highlight recent research on cancer therapy. Study 1: mTOR inhibitors augment the antiangiogenic value of radiation therapy. According to a study from the United States, "it is known that radiation activates the phosphoinositol-3 kinase (PI3K)/Akt pathway and that inhibition of PI3K or Akt sensitizes tumor vasculature to radiotherapy. Mammalian target of rapamycin (mTOR) is a downstream target of Akt, and we hypothesized that irradiation activates mTOR signaling in both glioma and endothelial cells (ECs) and that radiosensitization results from inhibiting mTOR signaling." "mTOR...
Source: Drug Week (2005-11-18)
|
